#Neulandlabs
Your question was absolutely spot on. @AdityaKhemka5
Challenges in the Levetiracetam sales were there for the past few quarters. Management always tried to convey the issues to be temporary.
Same old explanation.
Snippets to understand the progressionπ
Your question was absolutely spot on. @AdityaKhemka5
Challenges in the Levetiracetam sales were there for the past few quarters. Management always tried to convey the issues to be temporary.
Same old explanation.
Snippets to understand the progressionπ
Q3 FY21: Levetiracetam & Mirtazepine are the key growth drivers in GDS. Will continue to invest in those molecules and become market leaders.
Q4 FY21: GDS business was led by key molecules Levetiracetam & Mirtazepine.
Q1 FY22: We have gained market share and increased margins on Levetiracetam & Mirtazepine.
Q2 FY22: For Levetiracetam, we're strong in the markets that we're in but we're NOT seeing very strong spurt over there.
Reason- these are also the *CYCLES* that you have for these products.
Reason- these are also the *CYCLES* that you have for these products.
Q3FY22: Products which were historically doing well like Levetiracetam & Mirtazepine didn't perform to our expectations.
Reason- Lower customer off take & customer holding on to inventory from the orders in the past or they don't have a production campaign or need right now.
Reason- Lower customer off take & customer holding on to inventory from the orders in the past or they don't have a production campaign or need right now.
Q4FY22: Levetiracetam which has been doing well for us historically had challenges this year.
Reason- We believe that this is because of low customer off take, perhaps because of high inventories and we expect that the volumes should recover in coming quarters.
Reason- We believe that this is because of low customer off take, perhaps because of high inventories and we expect that the volumes should recover in coming quarters.
Today's con call
Q1 FY23: Biggest impact in the GDS was from Levetirazetam. It is also the largest product in our GDS segment which impacted our performance. We think it is temporary.
Reason- because of combination of reduction in demand & inventory build up at customer's end.
Q1 FY23: Biggest impact in the GDS was from Levetirazetam. It is also the largest product in our GDS segment which impacted our performance. We think it is temporary.
Reason- because of combination of reduction in demand & inventory build up at customer's end.
neulandlabs.com
You can hear the Q1FY23 earnings call recording from 34:13 for this particular question.
You can hear the Q1FY23 earnings call recording from 34:13 for this particular question.
On May 2021, big daddy Divi's talked about expanding Levetiracetam business with some changes (backward integration, increasing yield, solvent recovery) & to be completed within 3 months.
From Oct 2021, Neuland faced challenges in Levetiracetam business.
Now you know.
From Oct 2021, Neuland faced challenges in Levetiracetam business.
Now you know.
Loading suggestions...